RDNT Stock Analysis: RadNet | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 5.419m USD | 12M Return: 14.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 58.9M
EPS Trend: -51.1%
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 8
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RadNet, Inc. (NASDAQ: RDNT) is a U.S.-headquartered provider of outpatient diagnostic imaging services operating across two segments: Imaging Centers and Digital Health. Founded in 1981 and based in Los Angeles, the company offers a broad suite of imaging modalities, including MRI, CT, PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, and fluoroscopy, along with multi-modality imaging services delivered through its outpatient center network.
Beyond imaging facilities, RadNet generates revenue from healthcare software and artificial intelligence products, including picture archiving and communications systems (PACS), AI suites designed to assist radiologists in interpreting breast, lung, and prostate images, AI-powered health informatics for outpatient radiology, and DeepHealth OS, a cloud-native operating system for radiology operations. The company serves customers in the United States and internationally.
The outpatient diagnostic imaging industry has increasingly shifted volume away from hospital-based settings toward freestanding centers, driven by lower costs, greater patient convenience, and referring physician preference. At the same time, the application of AI tools to image interpretation and radiology workflow has become a growing area of investment across the healthcare services sector, positioning vendors with integrated imaging and software offerings to benefit from rising imaging volumes and demand for efficiency.
- AI mammography and lung screening drive Digital Health revenue
- Medicare reimbursement cuts pressure imaging center margins
- Acquisition pipeline expands outpatient imaging footprint
| Net Income: -14.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA -6.16 > 1.0 |
| NWC/Revenue: 4.90% < 20% (prev 27.31%; Δ -22.40% < -1%) |
| CFO/TA 0.09 > 3% & CFO 349.6m > Net Income -14.2m |
| Net Debt (2.33b) to EBITDA (324.0m): 7.18 < 3 |
| Current Ratio: 1.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (77.1m) vs 12m ago 3.60% < -2% |
| Gross Margin: 9.38% > 18% (prev 11.92%; Δ -2.54% > 0.5%) |
| Asset Turnover: 59.39% > 50% (prev 56.03%; Δ 3.36% > 0%) |
| Interest Coverage Ratio: 1.46 > 6 (EBIT TTM 102.5m / Interest Expense TTM 70.3m) |
| A: 0.03 (Total Current Assets 740.8m - Total Current Liabilities 635.6m) / Total Assets 3.89b |
| B: -0.03 (Retained Earnings -128.9m / Total Assets 3.89b) |
| C: 0.03 (EBIT TTM 102.5m / Avg Total Assets 3.61b) |
| D: 0.43 (Book Value of Equity 1.08b / Total Liabilities 2.53b) |
| Altman-Z'' = 0.71 = B |
| DSRI: 0.82 (Receivables 220.1m/235.0m, Revenue 2.14b/1.87b) |
| GMI: 1.27 (GM 11.92% / 9.38%) |
| AQI: -0.09 (AQ_t -0.03 / AQ_t-1 0.28) |
| SGI: 1.15 (Revenue 2.14b / 1.87b) |
| TATA: -0.09 (NI -14.2m - CFO 349.6m) / TA 3.89b) |
| Beneish M = -3.48 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 65.60 with a total of 366,255 shares traded. Over the past week, the price has changed by -4.58%, over one month by +12.79%, over three months by +18.35% and over the past year by +14.09%.
Current recommended Stop Loss: 61.90 (which is 5.6% or 1.3 ATR below the current price).
RadNet has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy RDNT.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 89.8 | 36.8% |
P/E Forward = 36.63
P/S = 2.521
P/B = 5.0031
P/EG = 0.9574
Revenue TTM = 2.14b USD
EBIT TTM = 102.5m USD
EBITDA TTM = 324.0m USD
Long Term Debt = 1.06b USD (from longTermDebt, last quarter)
Short Term Debt = 93.1m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 847.9m
Net Debt = 2.33b USD (calculated: Debt 2.78b - CCE 455.3m)
Enterprise Value = 7.75b USD (5.42b + Debt 2.78b - CCE 455.3m)
Interest Coverage Ratio = 1.46 (Ebit TTM 102.5m / Interest Expense TTM 70.3m)
EV/FCF = -52.08x (Enterprise Value 7.75b / FCF TTM -148.7m)
FCF Yield = -1.92% (FCF TTM -148.7m / Enterprise Value 7.75b)
FCF Margin = -6.94% (FCF TTM -148.7m / Revenue TTM 2.14b)
Net Margin = -0.66% (Net Income TTM -14.2m / Revenue TTM 2.14b)
Gross Margin = 9.38% ((Revenue TTM 2.14b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = -2.85% (prev 13.86%)
Tobins Q-Ratio = 1.99 (Enterprise Value 7.75b / Total Assets 3.89b)
Interest Expense / Debt = 2.53% (Interest Expense 70.3m / Debt 2.78b)
Taxrate = 31.55% (10.2m / 32.2m)
NOPAT = 70.2m (EBIT 102.5m * (1 - 31.55%))
Current Ratio = 1.17 (Total Current Assets 740.8m / Total Current Liabilities 635.6m)
Debt / Equity = 2.57 (Debt 2.78b / totalStockholderEquity, last quarter 1.08b)
Debt / EBITDA = 7.18 (Net Debt 2.33b / EBITDA 324.0m)
Debt / FCF = -15.64 (negative FCF - burning cash) (Net Debt 2.33b / FCF TTM -148.7m)
Total Stockholder Equity = 1.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.39% (Net Income -14.2m / Total Assets 3.89b)
RoE = -1.36% (Net Income TTM -14.2m / Total Stockholder Equity 1.04b)
RoCE = 4.88% (EBIT 102.5m / Capital Employed (Equity 1.04b + L.T.Debt 1.06b))
RoIC = 2.17% (NOPAT 70.2m / Invested Capital 3.24b)
WACC = 7.16% (E(5.42b)/V(8.20b) * Re(9.94%) + D(2.78b)/V(8.20b) * Rd(2.53%) * (1-Tc(0.32)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.44 | Cagr: 5.78%
[DCF] Fair Price = unknown (Cash Flow -148.7m)
EPS Correlation: -51.10 | EPS CAGR: -19.86% | SUE: -0.80 | # QB: 0
Revenue Correlation: 99.75 | Revenue CAGR: 12.47% | SUE: 1.95 | # QB: 8
EPS current Quarter (2026-06-30): EPS=0.20 | Chg30d=N/A | Revisions=+0% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.26 | Chg30d=N/A | Revisions=+22% | Analysts=6
EPS current Year (2026-12-31): EPS=0.52 | Chg30d=N/A | Revisions=-22% | GrowthEPS=+32.2% | GrowthRev=+21.9%
EPS next Year (2027-12-31): EPS=0.94 | Chg30d=N/A | Revisions=-12% | GrowthEPS=+82.9% | GrowthRev=+10.3%
[Analyst] Revisions Ratio: -4% (up=11, down=12)